- Home
- PRME vs ANAB Comparison
PRME vs ANAB Comparison
Compare PRME & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- ANAB
- Stock Information
- Founded
- PRME 2019
- ANAB 2005
- Country
- PRME United States
- ANAB United States
- Employees
- PRME N/A
- ANAB N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- ANAB Health Care
- Exchange
- PRME Nasdaq
- ANAB Nasdaq
- Market Cap
- PRME 624.0M
- ANAB 630.2M
- IPO Year
- PRME 2022
- ANAB 2017
- Fundamental
- Price
- PRME $3.72
- ANAB $21.90
- Analyst Decision
- PRME Buy
- ANAB Buy
- Analyst Count
- PRME 6
- ANAB 10
- Target Price
- PRME $8.88
- ANAB $48.00
- AVG Volume (30 Days)
- PRME 3.0M
- ANAB 465.1K
- Earning Date
- PRME 08-07-2025
- ANAB 11-04-2025
- Dividend Yield
- PRME N/A
- ANAB N/A
- EPS Growth
- PRME N/A
- ANAB N/A
- EPS
- PRME N/A
- ANAB N/A
- Revenue
- PRME $4,961,000.00
- ANAB $123,164,000.00
- Revenue This Year
- PRME $179.58
- ANAB $11.22
- Revenue Next Year
- PRME N/A
- ANAB $8.35
- P/E Ratio
- PRME N/A
- ANAB N/A
- Revenue Growth
- PRME 739.42
- ANAB 304.17
- 52 Week Low
- PRME $1.11
- ANAB $12.21
- 52 Week High
- PRME $5.17
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- PRME 54.32
- ANAB 52.43
- Support Level
- PRME $3.09
- ANAB $19.86
- Resistance Level
- PRME $3.49
- ANAB $22.98
- Average True Range (ATR)
- PRME 0.25
- ANAB 1.00
- MACD
- PRME 0.01
- ANAB 0.35
- Stochastic Oscillator
- PRME 95.49
- ANAB 69.14
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).